E-cadherin在晚期上皮性卵巢癌原发灶和转灶中的表达及意义

发布时间：2018-06-23 21:09

本文选题：卵巢癌 + E-cadherin　；参考：《石河子大学》2014年硕士论文

【摘要】：目的：通过检测E-cadherin在晚期卵巢癌原发灶以及相应转移灶中的表达,分析E-cadherin在晚期卵巢癌侵袭、转移中的作用机制及临床意义，探讨卵巢癌患者的临床病理特征（年龄、组织分化、临床分期）对E-cadherin在卵巢癌中阳性表达率的影响，为以后研究E-cadherin在卵巢癌中的作用机制提供初步理论依据。方法：选取2007年6月至2013年6月就诊于石河子大学第一附属医院，，临床病理资料完整并经手术切除、病理医师证实为原发卵巢癌的标本，收集30例晚期卵巢癌患者的标本及相应转移灶标本30例、卵巢良性肿瘤标本28例（均由病理证实）。将这些晚期卵巢癌的原发灶以及相应转移灶、卵巢良性肿瘤组织制成组织芯片，应用免疫组织化学技术检测E-cadherin的表达情况。用SPSS17．0统计软件分析上述蛋白表达与卵巢癌患者部分临床病理参数关系。结果：1.E-cadherin免疫组化染色定位于胞膜和（或）胞质，E-cadherin在卵巢癌原发灶组、转移灶组、良性肿瘤组的阳性表达率分别为46.6%(14/30)、20%(6/30)、82.1%(23/28)，其中原发灶及相应转移灶组的阳性表达率均低于良性肿瘤组，差异具有显著性(χ2=22.5P＜0.001)；2.E-cadherin在卵巢癌转移灶组的阳性表达率低于原发灶组，两组的表达差异具有统计学意义(P＜0.05)。3.E-cadherin的表达在晚期上皮性卵巢癌原发灶中不同年龄段以及临床分期经统计学分析结果均为P＞0.05，无统计学意义；E-cadherin的表达水平在不同病理分级的卵巢癌中有显著性差异（P＜0.05），在高分化卵巢癌中E-cadherin表达的平均水平高于中、低分化的肿瘤。结论：E-cadherin的低表达可能与卵巢癌的侵袭转移密切相关，E-cadherin表达降低可作为评估卵巢癌浸润转移能力的指标。
[Abstract]:Objective: to investigate the expression of E-cadherin in the primary and metastatic tumors of advanced ovarian cancer, to analyze the mechanism and clinical significance of E-cadherin in the invasion and metastasis of advanced ovarian cancer, and to explore the clinicopathological features of patients with advanced ovarian cancer. The effect of tissue differentiation and clinical stage on the positive expression of E-cadherin in ovarian cancer provides a theoretical basis for the further study of the mechanism of E-cadherin in ovarian cancer. Methods: selected from June 2007 to June 2013 at the first affiliated Hospital of Shihezi University, the clinicopathological data were complete and surgically resected, pathologists confirmed the specimens of primary ovarian cancer. 30 cases of advanced ovarian cancer and 30 cases of metastasis were collected, and 28 cases of benign ovarian tumors were collected (all confirmed by pathology). Tissue microarray was made from the primary tumor and the corresponding metastasis of these advanced ovarian cancer tissues, and the expression of E-cadherin was detected by immunohistochemical technique. SPSS 17.0 statistical software was used to analyze the relationship between the above protein expression and some clinicopathological parameters of ovarian cancer patients. Results 1. The immunohistochemical staining of E-cadherin was located in the primary tumor group of ovarian cancer and the metastatic tumor group, and was located in the cell membrane and / or cytoplasm of E-cadherin. The positive rate of positive expression in benign tumor group was 46.6% (14 / 30) or 20% (6 / 30) or 82.1% (23 / 28) respectively. The positive rate of positive expression in primary tumor group and corresponding metastatic tumor group was lower than that in benign tumor group (蠂 ~ 2 + 22.5 P < 0.001) 2.The positive rate of E-cadherin in ovarian cancer metastasis group was lower than that in primary tumor group. The expression of E-cadherin was significantly different between the two groups (P < 0.05). 3. The expression of E-cadherin in the primary lesions of advanced epithelial ovarian cancer was statistically significant (P > 0.05), and there was no significant difference in the expression of E-cadherin in different age groups and clinical stages of advanced epithelial ovarian cancer (P > 0.05). The expression level of E-cadherin was significantly different in ovarian cancer with different pathological grade (P < 0.05), and the average expression level of E-cadherin in well-differentiated ovarian carcinoma was higher than that in moderately and poorly differentiated ovarian carcinoma (P < 0.05). Conclusion the low expression of E-cadherin may be closely related to the invasion and metastasis of ovarian cancer. The decreased expression of E-cadherin may be used as an index to evaluate the ability of invasion and metastasis of ovarian cancer.
【学位授予单位】：石河子大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.31

【参考文献】